Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arbutus Biopharma CorpABUS · Entity 4953 | Chief Development Officer | January 20, 2022 | January 20, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arbutus Biopharma Corp
Report date January 20, 2022 · Filed January 20, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.81 · Expires 2032-01-20 | Direct | 256,500 |
Reported balance
After 2022-01-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-01-20 · Grant · Acquired 256,500 · Balance 256,500 F1: These stock options will vest and become exercisable 1/48th each month over the four year period. |
Filing footnotes · ownership attribution and instrument terms
F1: These stock options will vest and become exercisable 1/48th each month over the four year period.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 20, 2022 Filed Jan 20, 2022 22:54 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantStock Option (Right to Buy) · Derivative | 256,500 | $2.81 Strike: $2.81 | $720,765.00 |
DisclosureSEC source: 0001447028-22-000008 · wf-form4_164271923431244.xml · derivative · entry 1 Picchio Gaston · CIK 0001755014 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,500 Underlying: Common Shares · 256,500 shares Expires 2032-01-20 F1 · derivative.exercise_date: These stock options will vest and become exercisable 1/48th each month over the four year period. Read SEC document |
| February 13, 2021 Filed Feb 17, 2021 22:08 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantStock Options · Derivative | 250,000 | $0.00 Strike: $4.33 | $0.00 |
DisclosureSEC source: 0001447028-21-000014 · wf-form4_161359969444382.xml · derivative · entry 1 Picchio Gaston · CIK 0001755014 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2031-02-13 F1 · derivative.exercise_date: The stock option will vest and become exercisable 1/48th each month over the four year period. Read SEC document |
| September 23, 2020 Filed Sep 25, 2020 20:06 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantCommon Stock · Derivative | 50,000 | $0.00 Strike: $3.35 | $0.00 |
DisclosureSEC source: 0001447028-20-000144 · wf-form4_160106438963827.xml · derivative · entry 1 Picchio Gaston · CIK 0001755014 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2020-02-17 F1 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on February 14, 2020, the trading day immediately preceding the date the performance based option grant wasapproved by the Executive Compensation and Human Resources Committee of the Board of Directors (the "Committee") of Arbutus Biopharma Corporation, subject to both shareholder approval of anamendment to the Registrant's 2016 Omnibus Share and Incentive Plan (the "Plan Amendment") and the fulfillment of certain performance criteria. F2 · derivative.exercise_date: The Registrant's shareholders approved the Plan Amendment on May 28, 2020. On September 23, 2020, the Committee determined that the performance criteria had been met. Read SEC document |
| February 17, 2020 Filed Feb 19, 2020 13:04 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantStock Options · Derivative | 150,000 | $0.00 Strike: $3.35 | $0.00 |
DisclosureSEC source: 0001447028-20-000029 · wf-form4_158211747537119.xml · derivative · entry 1 Picchio Gaston · CIK 0001755014 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2030-02-17 F1 · derivative.exercise_date: The stock option will vest and become exercisable 1/48th each month over the four year period. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 23:09 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantEmployee Stock Option (Right to Buy) · Derivative | 137,500 | $0.00 Strike: $4.57 | $0.00 |
DisclosureSEC source: 0001123292-19-000438 · edgar.xml · derivative · entry 1 Picchio Gaston · CIK 0001755014 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,500 Underlying: Common Shares · 137,500 shares Expires 2029-03-01 F1 · derivative.exercise_date: The option will vest and become exercisable in three equal annual installments beginning March 1, 2020. Read SEC document |
| October 08, 2018 Filed Oct 10, 2018 18:20 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantEmployee Share Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $9.38 | $0.00 |
DisclosureSEC source: 0001567619-18-003919 · doc1.xml · derivative · entry 1 Picchio Gaston · CIK 0001755014 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Shares · 200,000 shares Expires 2028-10-08 F1 · derivative.exercise_date: The options vest as follows: 1/3 on 10/8/2019; 1/3 on 10/8/2020; and 1/3 on 10/8/2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.